Abstract
Background
Serum selenium concentrations and the activity of plasma glutathione peroxidase (GPx) decrease with the progression of chronic kidney disease (CKD) in human patients. Selenium is considered a limiting factor for plasma GPx synthesis. Plasma total antioxidant capacity (TAC) is decreased in CKD cats in comparison to healthy cats.
Hypothesis
Serum selenium concentrations and plasma and erythrocyte GPx activity in cats with CKD are lower than in healthy cats. Serum selenium concentrations, the activity of enzymes, and plasma TAC progressively decrease with the progression of kidney disease according to IRIS (International Renal Interest Society) classification.
Animals
Twenty‐six client‐owned cats in IRIS stages I–IV of CKD were compared with 19 client‐owned healthy cats.
Methods
A CBC, serum biochemical profile, urinalysis, plasma and erythrocyte GPx activity, serum selenium concentration, and plasma TAC were measured in each cat.
Results
Cats in IRIS stage IV CKD had a significantly higher (P = .025) activity of plasma GPx (23.44 ± 6.28 U/mL) than cats in the control group (17.51 ± 3.75 U/mL). There were no significant differences in erythrocyte GPx, serum selenium concentration, and plasma TAC, either among IRIS stages I–IV CKD cats or between CKD cats and healthy cats.
Conclusions and Clinical Importance
Erythrocyte GPx activity, serum selenium concentration, and plasma TAC do not change in CKD cats compared with healthy cats. Selenium is not a limiting factor in feline CKD. Increased plasma GPx activity in cats with stage IV CKD suggests induction of antioxidant defense mechanisms. Antioxidant defense systems might not be exhausted in CKD in cats.
Keywords: Antioxidants, Cats, Oxidative stress, Renal failure
Abbreviations
- CAT
catalase
- CKD
chronic kidney disease
- ETAAS
electrothermal atomic absorption spectrometry
- FeLV
feline leukemia virus
- FIV
feline immunodeficiency virus
- GPx
glutathione peroxidase
- HSD
honestly significant difference
- IRIS
International Renal Interest Society
- ROS
reactive oxygen species
- SOD
superoxide dismutase
- TAC
total antioxidant capacity
Chronic kidney disease (CKD) is a common condition in geriatric cats.1 It is characterized by progressive loss of kidney function, which results in renal fibrosis, uremia, and death.2 In human uremic patients, a state of imbalance between pro‐oxidative and antioxidative processes has been established, and defined as oxidative stress with increased amounts of reactive oxygen species (ROS) present.3, 4, 5 ROS are involved in cell signaling and cause activation of proinflammatory and mitogenic cellular pathways, which enhance the progression of renal fibrosis and cause a progressive decline in renal function.5, 6, 7 Glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase (CAT), and nitric oxide synthase are the most important antioxidant enzymes that detoxify ROS molecules in the kidneys.4
Two forms of GPx have been identified in human blood: plasma and erythrocyte GPx. The major synthetic site of plasma GPx is the proximal tubule in the kidneys.8 Plasma GPx also may function as an antioxidant in the renal tubules and extracellular space.9 The activity of GPx is decreased in human CKD patients. Plasma GPx activity therefore is an important diagnostic and prognostic factor of CKD in humans.3, 10, 11
Erythrocyte GPx is predominantly present in erythrocytes, kidney, and liver.9, 12 Some studies report that erythrocyte GPx activity is significantly increased early in the development of CKD, but remains stable until progression to end‐stage kidney disease.3 Other studies showed no significant differences in erythrocyte GPx activities between CKD patients and healthy controls.10, 13 In contrast, other studies reported a significant decrease in erythrocyte GPx activity in CKD patients in comparison to a control group.13, 14, 15
Selenium is an integral part of several selenoproteins, including glutathione peroxidases, and is present in food rich in protein.16 Cats have higher blood selenium concentrations than other species.17 They maintain selenium homeostasis by modulating its urinary excretion.18, 19 In human uremic patients, whole blood and serum concentrations of selenium are decreased because of either lower dietary intake or increased excretion. Furthermore, plasma selenium and plasma GPx concentrations have been found to be significantly lower in humans with end‐stage kidney disease.13, 20
To date, 2 studies evaluating oxidative stress in cats with CKD have been published.21, 22 Yu and Paetau‐Robinson21 investigated oxidative stress and the effects of dietary antioxidant supplementation on the oxidative status of cats with CKD. Their study showed that antioxidant supplements may be beneficial in cats with CKD.21 Keegan and colleagues studied oxidative stress parameters and neutrophil function in cats with CKD.22 Their results indicated that antioxidant defense mechanisms were activated in diseased cats.22
The purpose of the present study was to investigate plasma and erythrocyte GPx activity, serum selenium concentration, and plasma total antioxidant capacity (TAC) in cats with IRIS23 stages I–IV CKD. The objective of the present study was to test the hypotheses that serum selenium concentrations, plasma and erythrocyte GPx activity, and plasma TAC in cats with CKD are lower than in healthy cats. These parameters decrease with the progression of CKD according to the IRIS classification.
Materials and Methods
Selection of Cats
The study was performed at the Clinic for Surgery and Small Animal Medicine at the Veterinary Faculty in Ljubljana from September 2009 to March 2011. A detailed history was taken, and physical examination, CBC, serum biochemistry, and urinalysis were performed. Based on the examination and laboratory findings, the cats were divided into 2 groups: a control group and a group of cats with CKD.
Inclusion Criteria
Cats of all ages, breeds, and both sexes were considered for enrollment. Using available history, physical examination, hematology, biochemistry, urinalysis, and urine protein/creatinine ratio (UPC) data, cats were divided into 2 groups: a control group and cats with CKD. To be diagnosed with CKD, cats had to have serum creatinine concentration above the reference range (140 μmol/L) on at least 2 occasions (except IRIS stage I cats) and show clinical signs such as polyuria and polydipsia, and palpably small kidneys. In cats with IRIS stage 1 CKD, serum creatinine concentration was within the reference range. Cats with CKD were classified into 4 stages following IRIS guidelines: stage I (serum creatinine concentration <140 μmol/L), stage II (serum creatinine concentration: 140–249 μmol/L), stage III (serum creatinine concentration 250–439 μmol/L), and stage IV (serum creatinine concentration >440 μmol/L).23
Cats in the control group were determined to be healthy based on history, physical examination, and the results of hematology, biochemistry, and urinalysis. Urine specific gravity in healthy cats had to be >1.035.
All owners signed an informed consent form before enrolling their cats in the study. All procedures compiled with the relevant Slovenian governmental regulations (Animal Protection Act, Official Gazette of the Republic of Slovenia, No. 43/2007).
Exclusion Criteria
Cats with acute kidney injury, prerenal or postrenal azotemia, nephropathy of toxic or infectious origin within the previous 28 days, urinary tract obstruction, acute systemic inflammation, liver disease, chronic heart failure, cancer, or those that tested positive for feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), or both were excluded from the study.
Blood and Urine Sampling and Processing
Blood samples were collected from the jugular vein and transferred to serum separator tubes1 for the determination of serum biochemical profiles and for serologic detection of FeLV and FIV. The tubes were stored for 30 minutes at room temperature to clot, and then centrifuged at 1,300 × g for 10 minutes at room temperature to separate the serum. Serum samples were assayed on the day of collection. Biochemical profiles were determined with an automated biochemistry analyzer (RX Daytona2). An enzyme‐linked immunosorbent assay (ELISA) for the detection of antigen to FeLV and specific antibody to FIV were performed according to the manufacturer's instructions3 on the day of collection.
Blood samples for hematologic analysis were collected into ethylenediaminetetraacetic acid (EDTA)–containing tubes.4 EDTA blood samples were stored at room temperature and analyzed from 1 to 3 hours after sampling. Hematologic analyses were performed with an automated laser hematology analyzer ADVIA 1205 using species‐specific software.
Blood samples for determining plasma GPx activity and plasma TAC were collected into 2 mL tubes containing lithium heparin1 and immediately centrifuged at 1,500 × g for 15 minutes at 4°C. Plasma was separated and immediately frozen at −80°C until analysis. Activity of plasma GPx and plasma TAC in all samples collected was determined at the end of the study. The activity of human plasma GPx was shown to be stable for at least 4 years in samples stored at −76°C.24 Human serum or plasma TAC results were shown to be stable for 12 months when samples were stored at −70/80°C (or liquid nitrogen).25 Our personal data (unpublished results), based on several studies, showed that plasma TAC, determined in canine and equine plasma samples, is stable for at least 2 years.
Blood samples for determining GPx activity in erythrocytes were collected into 2‐mL tubes containing lithium heparin.1 Erythrocyte lysates were prepared immediately after blood collection, according to the manufacturer's (Ransod kit2) instructions, and stored at −80°C until analysis. Hemoglobin concentration in erythrocyte lysate was determined spectrophotometrically by the cyano‐methemoglobin method, using an automated biochemistry analyzer (RX Daytona).2 Activity of erythrocyte GPx in all samples collected was determined at the end of the study. The activity of human erythrocyte GPx was shown to be stable for 21 months when samples were stored at −80°C.26
Blood samples for serum selenium concentration determination were collected into 1.5‐ml Eppendorf tubes.6 They were stored for 30 minutes at 4°C to allow the blood to clot, and the tubes then were centrifuged at 1,300 × g for 10 minutes. Serum was frozen at −80°C until analysis. Serum selenium concentration in all samples collected was determined at the end of the study. Freezing at −20°C (or lower) for long‐term storage of human whole blood, plasma, and serum samples for trace element analysis (including selenium) for up to 2 years is recommended.27
Urine samples were collected by cystocentesis or catheterization. After collection, urinalysis was performed within 1–2 hours of sample collection. Analysis included measurement of specific gravity with a refractometer, use of a standard multitest urine dipstick, and microscopic examination of urine sediment. Urine samples were centrifuged at 800 × g for 10 minutes at room temperature. Urine supernatants were used for determination of protein and creatinine concentrations to calculate UPC. Protein and creatinine concentrations were measured with an automated biochemistry analyzer (RX Daytona)2 using colorimetric pyrogallol red2 and colorimetric picric acid2 methods, respectively. Protein concentrations were not determined in urine samples of cats when the urine sample was grossly contaminated with blood or contained spermatozoa.
Determination of GPx Activity
Plasma and erythrocyte GPx activity was measured spectrophotometrically with an automated biochemistry analyzer (RX Daytona)2 using a commercial Ransel kit,2 which is based on the method of Paglia and Valentine.28 The activity of plasma GPx was expressed as units per mL (U/mL) and the activity of erythrocyte GPx as units per grams of hemoglobin (U/gHgb).
Determination of Serum Selenium Concentrations
Serum selenium concentrations were measured by electrothermal atomic absorption spectrometry (ETAAS) using a Varian Spektr AA‐800 electrothermal atomic absorption spectrometer.7
Determination of Plasma TAC
Plasma samples were assayed for TAC with an automated biochemistry analyzer (RX Daytona)2 with a commercial total antioxidant status (TAS) kit,2 following the instructions of the kit. The assay29 is based on the reduction of free radicals (ABTS*+−2,2'–azinobis‐(3‐ehylbenzothiazoline‐6‐sulfonate)) measured as a decrease of absorbance at 600 nm at 3 minutes by antioxidants. The results are expressed as mmol/L of Trolox equivalents.
Statistical Analysis
Data were analyzed using the SPSS computer program.8 Descriptive statistics were used to describe the baseline data of the 2 groups of cats. The Shapiro–Wilk test was performed to test whether the data were normally distributed or not. Results are expressed as means ± standard deviation, unless stated otherwise. Values of selected blood parameters (serum selenium concentration, plasma and erythrocyte GPx, plasma TAC) were compared among groups of cats (4 groups of cats with different stages of feline CKD and healthy cats) using one‐way ANOVA and Tukey's HSD posthoc test. An unpaired t‐test was used to compare ages between the controls and clinical groups of cats (healthy versus IRIS stages I–IV). Posthoc power analysis using the general linear model/univariate approach also was performed. A value of P < .05 was considered significant.
Results
The characteristics of cats with CKD and healthy controls, as well as the details of the laboratory findings and signalment for each group of cats, are summarized in Tables 1 and 2, respectively. In the present study, 58 cats were evaluated; however, 2 of the cats with CKD were excluded from the study because they were positive for FeLV/FIV. In addition, 11 healthy cats were excluded because of inability to collect urine samples. Overall, 45 client‐owned cats were included in the study. Nineteen healthy cats were included in the control group. The group of cats with CKD consisted of 26 cats. Five cats were classified as stage I, 9 as stage II, 7 as stage III, and 5 as stage IV. The mean age of the healthy cats differed significantly (Table 1) in comparison with the mean age of stages I–IV CKD cats.
Table 1.
Summary of general characteristics for control cats and cats in IRIS stages I–IV of CKD
| Control (n = 19) | IRIS Stage I (n = 5) | IRIS Stage II (n = 9) | IRIS Stage III (n = 7) | IRIS Stage IV (n = 5) | |
|---|---|---|---|---|---|
| Age | |||||
| Mean ± SD (y) | 5.1 ± 5.1a | 11.0 ± 5.4b | 12.6 ± 6.6b | 13.4 ± 3.6b | 11.6 ± 3.6b |
| Range | 6264 m–19 y | 4–19 y | 3–21 y | 10–20 y | 7–17 y |
| P value | .027 | .002 | .000 | .011 | |
| Body weight (kg) Mean ± SD | 4.2 ± 1.5 | 4.1 ± 0.7 | 4.5 ± 1.2 | 3.1 ± 0.6 | 3.0 ± 0.7 |
| Sex (F/M) | 10/9 | 2/3 | 4/5 | 4/3 | 5/0 |
| Female intact | 4 | 0 | 0 | 0 | 0 |
| Female spayed | 6 | 2 | 4 | 4 | 5 |
| Male intact | 4 | 0 | 1 | 0 | 0 |
| Male neutered | 5 | 3 | 4 | 3 | 0 |
| Clinical signs | |||||
| Decreased appetite | 0/19 | 1/5 | 0/9 | 4/7 | 5/5 |
| Vomiting | 0/19 | 1/5 | 2/9 | 4/7 | 3/5 |
| Polyuria/polydipsia | 0/19 | 1/5 | 2/9 | 3/7 | 2/5 |
The P value indicates the significance of differences (P < .05; an unpaired t‐test) in age among clinical groups of cats (healthy versus. IRIS stages I–IV).
IRIS, International Renal Interest Society; CKD chronic kidney disease; n, number of cats; m, months; y, years; F/M, number of female/male cats.
Table 2.
Summary of laboratory findings for control cats and cats in IRIS stages I–IV of CKD
| Control, | IRIS Stage I, | IRIS Stage II, | IRIS Stage III, | IRIS Stage IV, | |
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
| Biochemical profile | (n = 19) | (n = 5) | (n = 9) | (n = 7) | (n = 5) |
| Urea (mmol/L) | 10.6 ± 3.5 | 12.8 ± 9.6 | 12.1 ± 3.3 | 27.9 ± 10.4 | 76.8 ± 37.5 |
| Creatinine (μmol/L) | 118.7 ± 23.0 | 122.2 ± 20.3 | 179.6 ± 31.8 | 296.9 ± 65.0 | 1081.3 ± 823.7 |
| AP (U/L) | 47.6 ± 43.9 | 25.2 ± 12.9 | 27.7 ± 7.3 | 28.0 ± 14.7 | 19.3 ± 5.0 |
| ALT (U/L) | 64.5 ± 41.1 | 68.2 ± 52.2 | 73.5 ± 31.7 | 120.8 ± 75.3 | 72.0 ± 40.3 |
| CBC | (n = 19) | (n = 5) | (n = 9) | (n = 7) | (n = 5) |
| WBC (×109/L) | 9.1 ± 3.6 | 8.0 ± 1.6 | 8.3 ± 3.9 | 15.1 ± 7.8 | 13.0 ± 10.0 |
| RBC (×1012/L) | 9.0 ± 1.3 | 7.8 ± 1.4 | 8.2 ± 1.3 | 7.2 ± 2.1 | 5.3 ± 1.4 |
| HCT (L/L) | 0.40 ± 0.06 | 0.36 ± 0.05 | 0.37 ± 0.06 | 33.1 ± 10.9 | 0.25 ± 0.06 |
| HGB (g/L) | 140.5 ± 66.1 | 112.0 ± 14.9 | 112.6 ± 18.5 | 103.9 ± 33.4 | 95.4 ± 25.7 |
| PLT (×109/L) | 255.6 ± 69.5 | 280.8 ± 98.5 | 318.7 ± 103.8 | 383.9 ± 196.7 | 336.4 ± 212.2 |
| Urinalysis | (n = 19) | (n = 4) | (n = 6) | (n = 7) | (n = 5) |
| Specific gravity | 1.062 ± 0.012 | 1.051 ± 0.020 | 1.043 ± 0.016 | 1.023 ± 0.006 | 1.019 ± 0.005 |
| (n = 11) | (n = 3) | (n = 5) | (n = 5) | (n = 4) | |
| UPC | 0.170 ± 0.104 | 6.341 ± 9.271 | 0.182 ± 0.129 | 0.747 ± 0.431 | 1.236 ± 0.939 |
IRIS, International Renal Interest Society; CKD, chronic kidney disease; n, number of cats; AP, alkaline phosphatase; ALT, alanine aminotransferase; CBC, complete blood count; WBC, white blood cells; RBC, red blood cells; HCT, hematocrit; HGB, hemoglobin; PLT, platelets; UPC, urine protein‐to‐creatinine ratio.
Laboratory findings (Table 1) indicated that mean serum creatinine concentrations in individual groups of cats varied according to IRIS guidelines for feline CKD stages I–IV.23 In healthy cats, the results of all laboratory parameters, with the exception of platelets, were within normal reference ranges.
Results for serum selenium concentration, activity of plasma and erythrocyte GPx, and plasma TAC are summarized in Table 3. There was no significant difference in serum selenium concentrations in CKD patients in comparison to the control group or among individual groups of CKD cats.
Table 3.
Serum selenium concentration, plasma and erythrocyte GPx activity, and plasma TAC level in cats in IRIS stages I–IV of CKD
| Serum Selenium (mg/L) | Plasma GPx (U/mL) | Erythrocyte GPx (U/gHgb) | Plasma TAC mmol/L | |
|---|---|---|---|---|
| IRIS Stage I (n = 5) | 0.465 ± 0.053 | 21.86 ± 2.04 | 591.18 ± 56.74 | 1.47 ± 0.18 |
| P value (versus control) | .807 | .534 | 1.000 | .990 |
| P value (versus IRIS stage II) | .934 | .913 | .998 | 1.000 |
| P value (versus IRIS stage III) | .904 | 1.000 | 1.000 | .581 |
| P value (versus IRIS stage IV) | .833 | .719 | .960 | .954 |
| IRIS Stage II (n = 9) | 0.426 ± 0.042 | 18.67 ± 1.66 | 582.51 ± 80.79 | 1.46 ± 0.16 |
| P value (versus control) | .999 | .940 | 1.000 | .964 |
| P value (versus IRIS stage I) | .934 | .912 | .998 | 1.000 |
| P value (versus IRIS stage III) | 1.000 | .912 | .992 | .482 |
| P value (versus IRIS stage IV) | .994 | .175 | .818 | .916 |
| IRIS Stage III (n = 7) | 0.419 ± 0.173 | 20.87 ± 2.56 | 603.92 ± 64.42 | 1.30 ± 0.13 |
| P value (versus control) | 1.000 | .464 | .998 | .134 |
| P value (versus IRIS stage I) | .904 | 1.000 | 1.000 | .581 |
| P value (versus IRIS stage II) | 1.000 | .912 | .992 | .482 |
| P value (versus IRIS stage IV) | .991 | .612 | .967 | .232 |
| IRIS Stage IV (n = 5) | 0.404 ± 0.077 | 23.44 ± 6.28 | 639.81 ± 27.78 | 1.68 ± 0.40 |
| P value (versus control) | .999 | .025 | .840 | .992 |
| P value (versus IRIS stage I) | .833 | .719 | .960 | .954 |
| P value (versus IRIS stage II) | .994 | .175 | .818 | .916 |
| P value (versus IRIS stage III) | .999 | .612 | .967 | .232 |
| Control group (n = 19) | 0.415 ± 0.091 | 17.51 ± 3.75 | 591.0 ± 111.21 | 1.51 ± 0.17 |
The P value indicates the significance of differences (P < .05; one‐way ANOVA) in measured parameters among clinical groups of cats (healthy versus IRIS stages I–IV and between IRIS stages I–IV).
CKD, chronic kidney disease; GPx, glutathione peroxidase; TAC, total antioxidant capacity; n, number of cats.
Significantly (P = .025) higher activity of plasma GPx was observed in stage IV CKD cats in comparison to the control group. However, there was no significant difference in plasma GPx activity between stages I–III CKD patients and the control group and among the 4 groups of CKD cats. Moreover, there was no significant difference in erythrocyte GPx activity and plasma TAC among any of the groups of cats.
Discussion
In the present study, a significantly higher activity of plasma GPx in stage IV CKD cats than in the control group was found. However, there were no significant differences in serum selenium concentration, plasma TAC, and erythrocyte GPx, either in cats at any stage of CKD in comparison to the control group or among individual groups of CKD cats.
The selenium concentrations in our study corresponded to those found in the healthy control group of cats in a study that compared selenium status and GPx activity in healthy and hyperthyroid cats.17 Furthermore, the study cited found no correlation between plasma GPx activity and selenium concentrations in the healthy or hyperthyroid cats. A correlation between selenium concentration and GPx activity was found only if the selenium intake was below the recommended amount. As soon as selenium concentrations reached recommended values, GPx activity reached its plateau value and did not increase further.17 In another study, the results showed no increase in erythrocyte and plasma GPx activities with increasing selenium intake at the amounts used in that study.18 It also was found that the selenium concentration in cat food was well above minimum recommended values. There seems to be enough selenium in the diet to fulfill the needs of diseased cats, and this trace element is not a limiting factor in feline CKD or in the synthesis of plasma GPx.17
In contrast, there is significant plasma and whole blood selenium deficiency in human end‐stage kidney disease patients.10, 20 In human patients with kidney disease, plasma selenium concentrations decrease as the disease progresses.3, 10, 20 The decrease in selenium concentrations is ascribed to low protein intake and increased protein loss attributable to proteinuria, which develops over the course of the disease.30 Lower selenium concentrations therefore could explain lower plasma GPx activity in human CKD patients. As carnivores, cats consume a diet that has a high concentration of proteins and therefore selenium is ingested in relatively high amounts. Cats therefore can tolerate greater selenium concentrations than other species.19 This may be the reason why cats with CKD do not have low serum selenium concentrations as human CKD patients do.
Several studies have reported decreased activity of plasma GPx in human chronic kidney disease patients, regardless of the stage of the disease.3, 11, 13, 14 Decreased GPx activity may be because of an increased rate of lipid peroxidation, a decrease in functional renal mass,3, 14, 20 the interference of uremic toxins,14, 20 plasma GPx consumption and inactivation by biochemical modification, or an abnormality in the hexose monophosphate pathway.20 Furthermore¸ the decrease in GPx activity also has been ascribed to selenium deficiency, because this microelement is a limiting factor for the synthesis of the enzyme.20 Other studies, however, have not suggested decreased GPx activity in association with low selenium intake.3, 13 The results of the present study showed no significant difference in the activity of plasma GPx in cats with stages I–III CKD, but significantly higher activity in cats with stage IV CKD when compared with a healthy cat population. The latter might reflect the presence of an adaptation mechanism by which the antioxidant system of these cats is enhanced and adapted to conditions of increased oxidative stress. The results indicate that antioxidant defense systems are not exhausted in stage IV feline CKD. A similar conclusion was reached by Keegan and Webb22 in a study performed on 20 cats with CKD. On the other hand, our results contrast with previous reports on plasma GPx activity in human CKD patients.3, 11, 13, 14 This might be because of differences in selenium metabolism between cats and humans. Selenium deficiency occurs in human CKD patients.10, 20 However, there seems to be no deficiency in cats with CKD, and the synthesis of plasma GPx is not impaired.
Total antioxidant capacity is a biochemical parameter suitable for evaluating the overall antioxidant status of plasma and body fluids resulting from antioxidant intake or production, and their consumption by normal or increased amounts of ROS production. The capacity of known and unknown antioxidants and their synergistic interaction therefore are assessed, thus giving insight into the delicate balance between oxidants and antioxidants in vivo.31, 32 The results of the present study demonstrated no significant difference in plasma TAC in cats with CKD in comparison to controls or among individual groups of CKD cats, thus indicating that systemic antioxidant defense systems might not be exhausted in CKD cats. Our result is in contrast with the study of Keegan and Webb22 who reported a significant decrease in antioxidant capacity in CKD cats compared with the healthy group of cats.22 The difference might be attributable to differences in the study design, because cats with CKD were not further classified in IRIS stages I–IV of CKD in the previous report.22 In part, the difference might be because of variations among the cats studied and because of differences in the spectrophotometric kits used for plasma TAC determination.
Erythrocyte GPx is considered the principal antioxidant enzyme for the detoxification of hydrogen peroxide in human erythrocytes.33 In human renal patients, its activity has been found to be increased,3 decreased13, 14 or not significantly different from healthy individuals.10, 34, 35 In the present study, the values of erythrocyte GPx activity in the control group and stages I–IV CKD patients were in agreement with published results in cats.36 No significant difference in its activity was found, either between the control group and the stages I‐IV CKD group or among individual groups of cats with CKD. This suggests that erythrocyte GPx activity does not depend on the pathophysiologic course of feline CKD.
Although the study reported here indicated that antioxidant defense systems might not be exhausted in feline CKD, this study had some limitations. These include low number of cats included in groups of IRIS stages I–IV of CKD, no age‐matching between control group and 4 groups of cats with CKD, and the use of only 1 method for plasma TAC determinations. Because low numbers of cats were included in groups of IRIS stages I–IV of CKD, posthoc power analyses were conducted. Statistically nonsignificant results may be the result of insufficient statistical power.37, 38 Posthoc power analyses indicated low power coefficients (less than the recommended 0.80)37 for statistically nonsignificant results, that is for serum selenium (0.118), erythrocyte GPx (0.123), and plasma TAC (0.468), which suggests ambiguity. On the other hand, much greater power was determined for plasma GPx (0.722), the parameter that was significantly higher in stage IV CKD patients in comparison to the control group. It would have been ideal to have had larger numbers of cats across the IRIS stages of CKD such that the difference in measured parameters would be greater and overlaps would not occur in the values measured.
To conclude, antioxidant defense systems might not be exhausted in feline CKD. Moreover, significantly higher plasma GPx activity in cats with stage IV of CKD suggests induction of the antioxidant enzyme defense system. Furthermore, there was no significant difference in serum selenium concentration, plasma TAC, or erythrocyte GPx activity, either when comparing the control group with CKD patients or among different stages of CKD patients. Selenium is therefore not a limiting factor in feline CKD, and erythrocyte GPx may not have a role in the course of this disease.
Acknowledgments
The authors thank Mr Martin Cregeen for review of English. The study was supported by grant no. P4‐0053 from the Slovenian Research Agency.
Conflict of Interest: Authors disclose no conflict of interest.
Footnotes
Vacuette; Greiner Bio‐One, Kremsmunster, Austria
Randox Laboratories, Crumlin, UK
SNAP feline triple, IDEXX Laboratories Inc, Westbrook, ME
BD Microtainer; Becton, Dickinson and Company, Franklin Lakes, NJ
SIEMENS, Munich, Germany
Eppendorf tubes, Brand, Wertheim, Germany
Varian Australia Pty Ltd, Mulgrave, Victoria, Australia
SPSS 17.0 for Windows, Chicago, IL
References
- 1. King JN, Tasker S, Gunn‐Moore DA, et al. Prognostic factors in cats with chronic kidney disease. J Vet Intern Med 2007;21:906–916. [PubMed] [Google Scholar]
- 2. Polzin DJ. Chronic kidney disease In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine, 7th ed St Louis, MO: Saunders; 2010:2036–2067. [Google Scholar]
- 3. Ceballos‐Picot I, Witko‐Sarsat V, Merad‐Boudia M, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996;21:845–853. [DOI] [PubMed] [Google Scholar]
- 4. Galle J. Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001;16:2135–2137. [DOI] [PubMed] [Google Scholar]
- 5. Wardle EN. Cellular oxidative processes in relation to renal disease. Am J Nephrol 2005;25:13–22. [DOI] [PubMed] [Google Scholar]
- 6. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44–84. [DOI] [PubMed] [Google Scholar]
- 7. Brown SA. Oxidative stress and chronic kidney disease. Vet Clin North Am Small Anim Pract 2008;38:157–166. [DOI] [PubMed] [Google Scholar]
- 8. Avissar N, Ornt DB, Yagi Y, et al. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 1994;266 (2 Pt 1):C367–C375. [DOI] [PubMed] [Google Scholar]
- 9. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci 2000;57:1825–1835. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Zachara B, Gromadzinska J, Wasowicz W, Zbrog Z. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: A review. Acta Biochim Pol 2006;53:663–677. [PubMed] [Google Scholar]
- 11. Schiavon R, Guidi GC, Biasioli S, et al. Plasma glutathione peroxidase activity as an index of renal function. Eur J Clin Chem Clin Biochem 1994;32:759–765. [DOI] [PubMed] [Google Scholar]
- 12. Mates JM. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 2000;153:83–104. [DOI] [PubMed] [Google Scholar]
- 13. Zachara BA, Salak A, Koterska D, et al. Selenium and glutathione peroxidases in blood of patients with different stages of chronic renal failure. J Trace Elem Med Biol 2004;17:291–299. [DOI] [PubMed] [Google Scholar]
- 14. El‐far MA, Bakr MA, Farahat SE, Abd El‐Fattah EA. Glutathione peroxidase activity in patients with renal disorders. Clin Exp Nephrol 2005;9:127–131. [DOI] [PubMed] [Google Scholar]
- 15. Durak I, Kavutcu M, Burak Çimen MY, et al. Oxidant/antioxidant status of erythrocytes from patients with chronic renal failure: Effects of hemodialysis. Med Princ Pract 2001;10:187–190. [Google Scholar]
- 16. Holben DH, Smith AM. The diverse role of selenium within selenoproteins: A review. J Am Diet Assoc 1999;99:836–843. [DOI] [PubMed] [Google Scholar]
- 17. Foster DJ, Thoday KL, Arthur JR, et al. Selenium status of cats in four regions of the world and comparison with reported incidence of hyperthyroidism in cats in those regions. Am J Vet Res 2001;62:934–937. [DOI] [PubMed] [Google Scholar]
- 18. Todd SE, Thomas DG, Bosch G, et al. Selenium status in adult cats and dogs fed high levels of dietary inorganic and organic selenium. J Anim Sci 2012;90:2549–2555. [DOI] [PubMed] [Google Scholar]
- 19. Todd SE, Thomas DG, Hendriks WH. Selenium balance in the adult cat in relation to intake of dietary sodium selenite and organically bound selenium. J Anim Physiol Anim Nutr 2012;96:148–158. [DOI] [PubMed] [Google Scholar]
- 20. Zagrodzki P, Barton H, Walas S, et al. Selenium status indices, laboratory data, and selected biochemical parameters in end‐stage renal disease patients. Biol Trace Elem Res 2007;116:29–41. [DOI] [PubMed] [Google Scholar]
- 21. Yu S, Paetau‐Robinson I. Dietary supplements of vitamins E and C and β‐carotene reduce oxidative stress in cats with renal insufficiency. Vet Res Commun 2006;30:403–413. [DOI] [PubMed] [Google Scholar]
- 22. Keegan RF, Webb CB. Oxidative stress and neutrophil function in cats with chronic renal failure. J Vet Intern Med 2010;24:514–519. [DOI] [PubMed] [Google Scholar]
- 23. Elliott J, Watson ADJ. Overview of the IRIS staging system for CKD (online) 2009. Available at: www.iris-kidney.com. Accessed February 25, 2012.
- 24. Trevisan M, Browne R, Ram M, et al. Correlates of markers of oxidative stress in the general population. Am J Epidemiol 2001;154:348–356. [DOI] [PubMed] [Google Scholar]
- 25. Jansen EH, Beekhof PK, Cremers JW, et al. Long‐term stability of parameters of antioxidant status in human serum. Free Radic Res 2013;47:535–540. [DOI] [PubMed] [Google Scholar]
- 26. Abiaka C, Al‐Awadi F, Olusi S. Effect of prolonged storage on the activities of superoxide dismutase, glutathione reductase, and glutathione peroxidase. Clin Chem 2000;46:560–576. [PubMed] [Google Scholar]
- 27. Subramanian KS. Storage and preservation of blood and urine for trace elements analysis. Biol Trace Elem Res 1995;49:187–210. [DOI] [PubMed] [Google Scholar]
- 28. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158–169. [PubMed] [Google Scholar]
- 29. Miller NJ, Rice–Evans CA, Davies MJ, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407–412. [DOI] [PubMed] [Google Scholar]
- 30. Allan CB, Lacourciere GM, Stadtman TC. Responsiveness of selenoproteins to dietary selenium. Annu Rev Nutr 1999;19:1–16. [DOI] [PubMed] [Google Scholar]
- 31. Prior RL, Cao G. In vivo total antioxidant capacity: Comparison of different analytical methods. Free Radic Biol Med 1999;27:1173–1181. [DOI] [PubMed] [Google Scholar]
- 32. Ghiselli A, Serafini M, Natella F, Scaccini C. Total antioxidant capacity as a tool to assess redox status: Critical view and experimental data. Free Radic Biol Med 2000;29:1106–1114. [DOI] [PubMed] [Google Scholar]
- 33. Izawa S, Inoue Y, Kimura A. Importance of catalase in the adaptive response to hydrogen peroxide: Analysis of acatalasaemic Saccharomyces cerevisiae . Biochem J 1996;320:61–67. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Yoshimura S, Suemizu H, Nomoto Y, et al. Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron 1996;73:207–211. [DOI] [PubMed] [Google Scholar]
- 35. Sommerburg O, Grune T, Ehrich JH, et al. Adaptation of glutathione‐peroxidase activity to oxidative stress occurs in children but not in adult patients with end‐stage renal failure undergoing hemodialysis. Clin Nephrol 2002;58:31–36. [PubMed] [Google Scholar]
- 36. Marshall MD, Wattam SL, Skinner ND, et al. Feline antioxidant enzyme activity: The effect of sample storage on stability. J Nutr 2002;132:1733S–1734S. [DOI] [PubMed] [Google Scholar]
- 37. Onwuegbuzie AJ, Leech NL. Post hoc power: A concept whose time has come. Understanding Stat 2004;3:201–230. [Google Scholar]
- 38. Yuan KH, Maxwell S. On the post hoc power in testing mean differences. J Educ Behav Stat 2005;30:141–167. [Google Scholar]